Search for Terms or Answers
Results for “What are the recent guidelines for treatment of SLE”
Jack Cush, MD · May 27, 2025
The ACR has released its 2025 Systemic Lupus Erythematosus (SLE) treatment guidelines and consensus-based good practice statements, applicable to children and adults with SLE.Overall, the goals of SLE management are to achieve remission or a low level disease activity, reduce morbidity and…
MedPage Today · Nov 10, 2025
Written by Lisa Sammaritano, MD, of the Hospital for Special Surgery in New York City, and a committee of nearly 50 other experts, the new guideline also stipulates that corticosteroids are OK for gaining symptom control in newly diagnosed patients and when flares erupt, but the duration should be kept as short as possible.
Karen Costenbader, MD, MPH · May 22, 2025
The paradigm for treating patients with systemic lupus erythematosus (SLE) is rapidly shifting and our patients will surely benefit with improved outcomes.
Michael Putman, MD, MSCI · Nov 21, 2024
Randomized controlled trials (RCTs) drive guidelines; guidelines drive clinical practice. Because updated guidelines lag trials by many years and dissemination of guidelines takes additional time, rheumatologists often practice “behind the data.” The 2024 ACR Guidelines for the Management of SLE Nephritis reaffirmed many of our typical practice patterns, including hydroxychloroquine for all, renin/angiotensin blockade, and favoring mycophenolate mofetil over cyclophosphamide.
Jack Cush, MD · May 15, 2025
The ACR has published evidence-based and expert guidance for the screening, treatment, and management of lupus nephritis (LN). These are the same guidelines presented at ACR Convergence 2024. A multidisciplinary team of experts performed systematic literature reviews to address specific PICO…
Guillermo Ruiz-Irastorza, MD, PhD · Dec 26, 2025
Current guidelines recommend limiting the use of glucocorticoids by coining the new concept of “bridging therapy”, that is, use GCs when the disease is active and get rid of them as soon as you can. This way of thinking is conceptually attractive, however, the formula for translation to real life settings is not included.
Janet Pope, MD, MPH, FRCPC · Jun 5, 2026
There are so many SLE trials, and over the last year, many new ideas have been suggested.
Jack Cush, MD · May 2, 2026
Dr. Cush reviews systemic lupus erythematosus.
Guillermo Ruiz-Irastorza, MD, PhD · May 5, 2025
Current guidelines recommend limiting the use of glucocorticoids by coining the new concept of “bridging therapy”, that is, use GCs when the disease is active and get rid of them as soon as you can. This way of thinking is conceptually attractive, however, the formula for translation to real life settings is not included.
Sponsored by Aurinia · Apr 17, 2026
Two experts in lupus care offer a balanced perspective on applying the updated ACR Guideline recommendations and the clinical nuances of managing lupus nephritis.
Jack Cush, MD · Oct 22, 2026
Professor van Vollenhoven has compiled a state-of-the-art review on lupus treatment advances – current and future. SLE management is entering an unprecedented phase.
Melissa Akselrad, MD · Nov 10, 2026
We call it systemic lupus erythematosus (SLE), but are we really treating one disease? Increasingly, I wonder whether grouping biologically distinct patients under one diagnosis is limiting our ability to treat them effectively.Two abstracts at ACR Convergence 2026 highlight the promise of…
Antoni Chan MD (Prof) · Nov 18, 2024
Updated ACR guidelines on management of lupus nephritis (LN). Consider early biopsy. Focus on triple therapy in LN. From the panel discussion, Tacrolimus can be an alternative to CNI (Voclosporin) where there is no access to this. Manage comorbidities such as CV risk, bone… https://t.co/4R02YnRXDP https://t.co/3J7YcF5ucQ
Jack Cush, MD · Jul 1, 2026
RheumNow recently surveyed clinicians to better understand current practice patterns, educational needs, and barriers to the use of new, advanced therapies in systemic lupus erythematosus (SLE). A total of 197 clinicians completed the survey.
Md Yuzaiful Md Yusof, MRCP(UK), PhD · Jun 16, 2025
At the 2025 EULAR congress in Barcelona, Prof Dimitrios Boumpas presented a summary of the updated EULAR recommendations on the management of lupus nephritis (LN). The most significant change in the treatment paradigm of LN is that the historic standard of care (SOC) (i.e. mycophenolate with…
janetpope · Jun 18, 2015
There are no detailed recommendations agreed upon by SLE experts on what treatment to use after first and second (and often third) line treatment has failed.
Md Yuzaiful Md Yusof, MRCP(UK), PhD · Jun 17, 2024
Glucocorticoids (GC) have been the mainstay of treatment in SLE for nearly three quarters of a century. GC induce a range of anti-inflammatory effects, quickly relieve some symptoms and lower mortality in some life-threatening flares. However, they also have multiple side effects that limit the duration of treatment, as well as the dose used. Accordingly, the 2023 EULAR recommendations for SLE set a target dose of ≤5mg/day. Is low dose GC an achievable target?
Sponsored by GSK US Medical Affairs · Sep 1, 2024
Learn about the importance of reducing organ damage and corticosteroid-associated toxicity in SLE, and how biologics may help to change the course of the disease by targeting its underlying mechanisms.
Catherine Sims, MD · May 12, 2025
Attendees at the 2025 RheumaPreg meeting were excited to discuss the newly released EULAR recommendations for use of antirheumatic drugs in reproduction, pregnancy, and lactation. Table 1 summarizes the major recommendations from EULAR (2025) and the American College of Rheumatology (2020) reproductive guidelines for commonly used medications in SLE. It should be noted that these two sets of guidelines largely align, however, the updated EULAR guidelines have included some additional medications incorporating data from the last five years.
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.